Milebot Robotics, a pioneering healthcare robotics firm specializing in the research, development, and production of rehabilitation and elderly care exoskeleton robots, along with human-machine interaction technologies, has recently announced the successful acquisition of nearly 100 million yuan in strategic investment from CSC Financial. Haoguan Capital played a pivotal role as the exclusive financial advisor in this transaction.

As the inaugural profitable enterprise within China's medical exoskeleton industry, Milebot Robotics adeptly balances profitability with technological sophistication through a methodical product strategy. The company is at the forefront of utilizing flexible actuators to facilitate active rehabilitation training and has developed proprietary biomechanical models to offer tailored solutions. This has enabled Milebot Robotics to establish a comprehensive product portfolio that spans in-hospital, community, and home-based care settings.

Its flagship products have not only secured Class II medical device certification from the National Medical Products Administration (NMPA) but have also achieved significant commercial success. The newly acquired funds will be strategically allocated towards the integration of advanced technologies and their clinical application, the expansion of its full-scenario product offerings, and the pursuit of international market expansion.